IMCR vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IMCR exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. While the company maintains an impressive gross margin of 96.53% and positive revenue growth of 24.3%, these are offset by a catastrophic year-over-year EPS decline of 452.9% and a bearish insider sentiment. There is a stark disconnect between the aggressive analyst target price of $63.86 and the actual deterministic data, which suggests a high-risk profile characterized by consistent earnings misses and insider liquidation.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IMCR vs JNJ: Head-to-Head Comparison
This page compares Immunocore Holdings plc (IMCR) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.